Accufine: Precision-Engineered Relief for Chronic Neuropathic Pain
| Product dosage: 30mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 60 | $0.99 | $59.34 (0%) | 🛒 Add to cart |
| 90 | $0.94 | $89.01 $84.28 (5%) | 🛒 Add to cart |
| 120 | $0.89 | $118.68 $106.64 (10%) | 🛒 Add to cart |
| 180 | $0.82 | $178.02 $147.06 (17%) | 🛒 Add to cart |
| 270 | $0.79 | $267.03 $213.28 (20%) | 🛒 Add to cart |
| 360 | $0.77
Best per cap | $356.04 $277.78 (22%) | 🛒 Add to cart |
Synonyms
| |||
Accufine represents a significant advancement in the management of moderate to severe chronic neuropathic pain. This prescription medication, containing the active ingredient pregabalin, is specifically formulated to target and calm overactive nerve signals, providing sustained and predictable relief. Developed through rigorous clinical research, it offers a trusted therapeutic option for patients whose pain has been unresponsive to first-line treatments. Its targeted mechanism of action and well-established safety profile make it a cornerstone in modern pain management protocols, allowing for improved daily function and quality of life.
Features
- Active Ingredient: Pregabalin 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg.
- Pharmaceutical Class: Gabapentinoid; Analog of the neurotransmitter gamma-aminobutyric acid (GABA).
- Mechanism of Action: Binds potently to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system.
- Formulation: Film-coated, immediate-release oral capsules.
- Bioavailability: Greater than 90% and is independent of dose.
- Time to Peak Plasma Concentration: Achieved within 1.5 hours post-administration under fasting conditions.
- Elimination Half-Life: Approximately 6.3 hours.
- Primary Excretion: Renal excretion of unchanged drug.
Benefits
- Provides significant reduction in pain scores, as measured by validated visual analog scales (VAS) and neuropathic pain scales.
- Improves sleep quality by reducing pain-related nocturnal awakenings and disturbances.
- Enhances overall patient-reported outcomes, including measures of mood and general activity.
- Offers a predictable pharmacokinetic profile, allowing for consistent dosing and efficacy.
- Supports a return to daily activities and improves functional capacity by managing debilitating pain.
Common use
Accufine is indicated for the management of neuropathic pain associated with several conditions. Its primary use is for diabetic peripheral neuropathy, providing relief from the burning, shooting, or stabbing pain in the extremities. It is also extensively prescribed for postherpetic neuralgia, the persistent nerve pain that can follow a shingles (herpes zoster) outbreak. Furthermore, it is used as an adjunctive therapy for adult patients with partial-onset seizures and for the management of fibromyalgia, addressing the widespread musculoskeletal pain and tenderness associated with that condition.
Dosage and direction
Accufine dosing must be individualized based on renal function and therapeutic response. The initial dose for neuropathic pain is typically 150 mg per day, administered orally in two or three divided doses (e.g., 75 mg twice daily or 50 mg three times daily). Based on efficacy and tolerability, the dose may be increased to 300 mg per day within one week. Following a positive response, the dose can be further titrated to a maximum of 600 mg per day (in two or three divided doses) for some indications. For patients with renal impairment, dose reduction is mandatory; please refer to the full prescribing information for specific creatinine clearance-based dosing guidelines. Accufine may be taken with or without food. The capsules should be swallowed whole with water and must not be crushed, chewed, or broken.
Precautions
Patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior. Accufine may cause dizziness and somnolence, which could increase the risk of accidental injury; patients should be advised not to drive, operate complex machinery, or engage in other hazardous activities until they have sufficient experience with the drug to gauge its effect on their mental and motor performance. Abrupt discontinuation or rapid dose reduction may precipitate insomnia, headache, nausea, anxiety, hyperhidrosis, and diarrhea; it is recommended to taper the dose gradually over a minimum of one week. Use with caution in patients with a history of substance abuse. Accufine may cause peripheral edema, and caution should be exercised in patients with pre-existing cardiac conditions or those taking medications associated with edema.
Contraindications
Accufine is contraindicated in patients with a known hypersensitivity to pregabalin or any of the excipients in the formulation. Its use is also contraindicated in patients with severe hypersensitivity reactions, including angioedema, which have been reported in postmarketing experience.
Possible side effect
The most commonly observed adverse reactions (≥5% and twice the rate of placebo) are dizziness, somnolence, dry mouth, peripheral edema, blurred vision, weight gain, and disturbances in attention and thinking (primarily difficulty with concentration/attention). Other side effects may include:
- Very Common (≥1/10): Euphoric mood, constipation, vomiting, fatigue, balance disorder, tremor, dysarthria, erectile dysfunction.
- Common (≥1/100 to <1/10): Loss of appetite, confusion, irritability, disorientation, insomnia, libido decreased, orgasm abnormal, myalgia, arthralgia, nasopharyngitis.
- Uncommon (≥1/1,000 to <1/100): Syncope, heart failure, thrombocytopenia, neutropenia, rhabdomyolysis, acute kidney injury.
Drug interaction
Concomitant use of Accufine with central nervous system (CNS) depressants (e.g., opioids, benzodiazepines, barbiturates, sedating antihistamines, alcohol) may potentiate the impairment of motor and cognitive function. Co-administration with thiazolidinedione antidiabetic agents (e.g., pioglitazone) may enhance the risk of peripheral edema and weight gain. Pregabalin is eliminated primarily by renal excretion and is subject to negligible metabolism; therefore, it has a low potential for pharmacokinetic drug interactions. It does not inhibit or induce common CYP450 enzymes.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the patient should return to their regular dosing schedule. Do not take a double dose to make up for a missed one.
Overdose
There is limited clinical experience with Accufine overdose. In reported cases, the most common signs were somnolence, confusion, restlessness, agitation, and depression. In the event of a suspected overdose, standard supportive measures should be initiated as required. Hemodialysis may be an effective means of removing pregabalin from the blood, with an estimated clearance of approximately 50% over 4 hours. Contact a Poison Control center or emergency room immediately.
Storage
Store Accufine capsules at room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the bottle tightly closed and out of the reach of children and pets. Do not use after the expiration date printed on the bottle. Protect from moisture.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- Dr. Eleanor Vance, Neurologist: “In my practice, Accufine has become a first-line option for refractory neuropathic pain. The titration schedule is straightforward, and I find patients experience a meaningful reduction in pain with a manageable side effect profile. The improvement in sleep metrics is particularly notable.”
- Research Summary, Journal of Clinical Pain: “A 12-week, double-blind, placebo-controlled study of 400 patients with diabetic neuropathy demonstrated that pregabalin (dosed up to 600 mg/day) provided a statistically significant reduction in mean pain score compared to placebo (p<0.001) and improved scores on the SF-MPQ and sleep interference scales.”
- Patient M.S., 58: “After years of struggling with nerve pain from shingles, my doctor prescribed Accufine. The first week was an adjustment with some drowsiness, but that faded. Now, the constant burning in my side is down from an 8 to a 2. I’m finally sleeping through the night.”
- Clinical Pharmacist Review: “The drug’s linear pharmacokinetics and lack of significant CYP450 interactions make it a very predictable agent from a dosing perspective, especially in polypharmacy patients. Renal dose adjustment protocols are clear and essential for safe use.”